The DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.
Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis
Open accessAbstract
Objectives To perform a systematic literature review (SLR) concerning the safety of synthetic (s) and biological (b) disease-modifying anti rheumatic dugs (DMARDs) to inform the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis (RA). Methods An SLR of observational studies comparing safety outcomes of any DMARD with another intervention for the management of RA. A comparator group was required for inclusion. For treatments still without registry data (eg, sarilumab and the Janus kinase (JAK) inhibitors baricitinib, upadacitinib), randomised controlled trials (RCTs) and long-term extensions (LTEs) were used. Risk of bias (RoB) was assessed according to standard procedures. Results Forty-two observational studies fulfilled the inclusion criteria, addressing safety outcomes with bDMARDs and sDMARDs. Nine studies showed no difference in the risk of serious infections across bDMARDs and two studies (high RoB) showed an increased risk with bDMARDs compared with conventional synthetic (cs) DMARDs (adjusted incidence rate ratio 3.1–3.9). The risk of Herpes zoster infection was similar across bDMARDs, but one study showed an increased risk with tofacitinib compared with abatacept (adjusted HR (aHR) 2.0). Five studies showed no increased risk of cancer for bDMARDs compared with csDMARDs. An increased risk of lower intestinal perforation was found for tocilizumab compared with csDMARDs (aHR 4.5) and tumour necrosis factor inhibitor (TNFi) (aHR 2.6–4.0). Sixty manuscripts reported safety data from RCTs/LTEs. Overall, no unexpected safety outcomes were found, except for the possibly increased risk of venous thromboembolism (VTE) with JAK inhibitors. Conclusion Data obtained by this SLR confirm the known safety profile of bDMARDs. The risk of VTE in RA, especially in patients on JAK inhibitors, needs further evaluation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
Evaluation of the Quality of Prognosis Studies in Systematic Reviews
Hayden, J. A., Côté, P., & Bombardier, C. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-6-200603210-00010 · Cited by 1,452
Götestam Skorpen, C., Hoeltzenbein, M., Tincani, A., Fischer-Betz, R., Elefant, E., Chambers, C., da Silva, J., Nelson-Piercy, C., Cetin, I., Costedoat-Chalumeau, N., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-208840 · Cited by 1,068
Furer, V., Rondaan, C., Heijstek, M. W., Agmon-Levin, N., van Assen, S., Bijl, M., Breedveld, F. C., D'Amelio, R., Dougados, M., Kapetanovic, M. C., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-215882 · Cited by 829
Self-citationBaricitinib in Patients with Refractory Rheumatoid Arthritis
Genovese, M. C., Kremer, J., Zamani, O., Ludivico, C., Krogulec, M., Xie, L., Beattie, S. D., Koch, A. E., Cardillo, T. E., Rooney, T. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1507247 · Cited by 627
Self-citationFleischmann, R., Mysler, E., Hall, S., Kivitz, A. J., Moots, R. J., Luo, Z., DeMasi, R., Soma, K., Zhang, R., Takiya, L., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31618-5 · Cited by 499
Self-citationFleischmann, R., Schiff, M., van der Heijde, D., Ramos‐Remus, C., Spindler, A., Stanislav, M., Zerbini, C. A. F., Gurbuz, S., Dickson, C., de Bono, S., et al. (2017) · Arthritis & Rheumatology · doi:10.1002/art.39953 · Cited by 427
Self-citationGenovese, M. C., Fleischmann, R., Combe, B., Hall, S., Rubbert-Roth, A., Zhang, Y., Zhou, Y., Mohamed, M.-E. F., Meerwein, S., & Pangan, A. L. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31116-4 · Cited by 422
Smolen, J. S., Landewé, R., Breedveld, F. C., Dougados, M., Emery, P., Gaujoux-Viala, C., Gorter, S., Knevel, R., Nam, J., Schoels, M., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.126532 · Cited by 409
Self-citationDougados, M., van der Heijde, D., Chen, Y.-C., Greenwald, M., Drescher, E., Liu, J., Beattie, S., Witt, S., de la Torre, I., Gaich, C., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210094 · Cited by 404
Self-citationCohen, S. B., Tanaka, Y., Mariette, X., Curtis, J. R., Lee, E. B., Nash, P., Winthrop, K. L., Charles-Schoeman, C., Thirunavukkarasu, K., DeMasi, R., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210457 · Cited by 393
Burmester, G. R., Kremer, J. M., Van den Bosch, F., Kivitz, A., Bessette, L., Li, Y., Zhou, Y., Othman, A. A., Pangan, A. L., & Camp, H. S. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31115-2 · Cited by 373
Self-citationRamiro, S., Sepriano, A., Chatzidionysiou, K., Nam, J. L., Smolen, J. S., van der Heijde, D., Dougados, M., van Vollenhoven, R., Bijlsma, J. W., Burmester, G. R., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210708 · Cited by 358
Self-citationCurtis, J. R., Xie, F., Yun, H., Bernatsky, S., & Winthrop, K. L. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209131 · Cited by 285
Yoo, D. H., Prodanovic, N., Jaworski, J., Miranda, P., Ramiterre, E., Lanzon, A., Baranauskaite, A., Wiland, P., Abud-Mendoza, C., Oparanov, B., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-208786 · Cited by 279
Duru, N., van der Goes, M. C., Jacobs, J. W. G., Andrews, T., Boers, M., Buttgereit, F., Caeyers, N., Cutolo, M., Halliday, S., Da Silva, J. A. P., et al. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-203249 · Cited by 273
Self-citationBurmester, G. R., Lin, Y., Patel, R., van Adelsberg, J., Mangan, E. K., Graham, N. M. H., van Hoogstraten, H., Bauer, D., Ignacio Vargas, J., & Lee, E. B. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210310 · Cited by 272
Self-citationProposal for a new nomenclature of disease-modifying antirheumatic drugs
Smolen, J. S., van der Heijde, D., Machold, K. P., Aletaha, D., & Landewé, R. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204317 · Cited by 256
Self-citationHerpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy
Winthrop, K. L., Curtis, J. R., Lindsey, S., Tanaka, Y., Yamaoka, K., Valdez, H., Hirose, T., Nduaka, C. I., Wang, L., Mendelsohn, A. M., et al. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40189 · Cited by 241
Giles, J. T., Sattar, N., Gabriel, S., Ridker, P. M., Gay, S., Warne, C., Musselman, D., Brockwell, L., Shittu, E., Klearman, M., et al. (2020) · Arthritis & Rheumatology · doi:10.1002/art.41095 · Cited by 240
Westhovens, R., Taylor, P. C., Alten, R., Pavlova, D., Enríquez-Sosa, F., Mazur, M., Greenwald, M., Van der Aa, A., Vanhoutte, F., Tasset, C., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210104 · Cited by 236
Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis
Harigai, M. (2019) · Rheumatology · doi:10.1093/rheumatology/key287 · Cited by 231
Kavanaugh, A., Kremer, J., Ponce, L., Cseuz, R., Reshetko, O. V., Stanislavchuk, M., Greenwald, M., Van der Aa, A., Vanhoutte, F., Tasset, C., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210105 · Cited by 229
Kim, S. C., Solomon, D. H., Rogers, J. R., Gale, S., Klearman, M., Sarsour, K., & Schneeweiss, S. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40084 · Cited by 195
Mercer, L. K., Askling, J., Raaschou, P., Dixon, W. G., Dreyer, L., Hetland, M. L., Strangfeld, A., Zink, A., Mariette, X., Finckh, A., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209285 · Cited by 188
Cohen, S., Genovese, M. C., Choy, E., Perez-Ruiz, F., Matsumoto, A., Pavelka, K., Pablos, J. L., Rizzo, W., Hrycaj, P., Zhang, N., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210459 · Cited by 185
Pawar, A., Desai, R. J., Solomon, D. H., Santiago Ortiz, A. J., Gale, S., Bao, M., Sarsour, K., Schneeweiss, S., & Kim, S. C. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-214367 · Cited by 181
Fleischmann, R., van Adelsberg, J., Lin, Y., Castelar‐Pinheiro, G. D. R., Brzezicki, J., Hrycaj, P., Graham, N. M. H., van Hoogstraten, H., Bauer, D., & Burmester, G. R. (2017) · Arthritis & Rheumatology · doi:10.1002/art.39944 · Cited by 178
Self-citationCardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis
Taylor, P. C., Weinblatt, M. E., Burmester, G. R., Rooney, T. P., Witt, S., Walls, C. D., Issa, M., Salinas, C. A., Saifan, C., Zhang, X., et al. (2019) · Arthritis & Rheumatology · doi:10.1002/art.40841 · Cited by 176
Self-citationStrangfeld, A., Richter, A., Siegmund, B., Herzer, P., Rockwitz, K., Demary, W., Aringer, M., Meißner, Y., Zink, A., & Listing, J. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209773 · Cited by 174
Wadström, H., Frisell, T., Askling, J., & for the Anti-Rheumatic Therapy in Sweden (ARTIS) Study Group (2017) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2017.4332 · Cited by 173
Choe, J.-Y., Prodanovic, N., Niebrzydowski, J., Staykov, I., Dokoupilova, E., Baranauskaite, A., Yatsyshyn, R., Mekic, M., Porawska, W., Ciferska, H., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-207764 · Cited by 171
Self-citationXie, F., Yun, H., Bernatsky, S., & Curtis, J. R. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39761 · Cited by 161
Low, A. S. L., Symmons, D. P. M., Lunt, M., Mercer, L. K., Gale, C. P., Watson, K. D., Dixon, W. G., & Hyrich, K. L. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209784 · Cited by 158
Yamanaka, H., Tanaka, Y., Takeuchi, T., et al. (2016) · Arthritis Research & Therapy · doi:10.1186/s13075-016-0932-2 · Cited by 154
Takeuchi, T., Tanaka, Y., Iwasaki, M., Ishikura, H., Saeki, S., & Kaneko, Y. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-208279 · Cited by 152
Thromboembolism with Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis: How Real is the Risk?
Scott, I. C., Hider, S., & Scott, D. L. (2018) · Drug Safety · doi:10.1007/s40264-018-0651-5 · Cited by 150
Smolen, J. S., Agarwal, S. K., Ilivanova, E. P., Xu, X. L., Ye, M., Zhuang, Y., Nnane, I. P., Radziszewski, W., Greenspan, A. J., Beutler, A. M., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209831 · Cited by 144
Self-citationWeinblatt, M. E., Baranauskaitė, A., Niebrzydowski, J., Dokoupilová, E., Zielinska, A. E., Jaworski, J., Racewicz, A. J., Pileckytė, M., Jedrychowicz‐Rosiak, K., Cheong, S. Y., et al. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40336 · Cited by 134
Gottenberg, J., Morel, J., Perrodeau, É., Bardin, T., Combe, B. G., Dougados, M., Flipo, R., Saraux, A., Schaeverbeke, T., Sibilia, J., et al. (2019) · BMJ · doi:10.1136/bmj.l67 · Cited by 134
Self-citationSmolen, J. S., Schoels, M., Nishimoto, N., Breedveld, F. C., Burmester, G. R., Dougados, M., Emery, P., Ferraccioli, G., Gabay, C., Gibofsky, A., et al. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202469 · Cited by 133
Self-citationBurmester, G. R., McInnes, I. B., Kremer, J. M., Miranda, P., Korkosz, M., Vencovský, J., Rubbert‐Roth, A., Mysler, E., Sleeman, M. A., Godwood, A., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210624 · Cited by 132
Self-citationGenovese, M. C., van Vollenhoven, R., Pacheco‐Tena, C., Zhang, Y., & Kinnman, N. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39473 · Cited by 130
Mercer, L., Galloway, J. B., Lunt, M., Davies, R., Low, A., Dixon, W. G., Watson, K. D., Symmons, D. P. M., & Hyrich, K. L. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209389 · Cited by 126
Winthrop, K. L., Wouters, A., Choy, E., Soma, K., Hodge, J. A., Nduaka, C. I., Biswas, P., Needle, E., Passador, S., Mojcik, C. F., et al. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40187 · Cited by 123
Weinblatt, M. E., Baranauskaitė, A., Dokoupilová, E., Zielinska, A. E., Jaworski, J., Racewicz, A. J., Pileckytė, M., Jedrychowicz‐Rosiak, K., Baek, I.-Y., & Ghil, J. (2018) · Arthritis & Rheumatology · doi:10.1002/art.40444 · Cited by 120
Desai, R. J., Pawar, A. M., Weinblatt, M. E., & Kim, S. C. (2018) · Arthritis & Rheumatology · doi:10.1002/art.40798 · Cited by 117
Richter, A., Listing, J., Schneider, M., Klopsch, T., Kapelle, A., Kaufmann, J., Zink, A., & Strangfeld, A. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-207838 · Cited by 115
Emery, P., Vencovský, J., Sylwestrzak, A., Leszczyński, P., Porawska, W., Stasiuk, B., Hilt, J., Mosterova, Z., Cheong, S. Y., & Ghil, J. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-211591 · Cited by 114
Zhang, J., Xie, F., Yun, H., Chen, L., Muntner, P., Levitan, E., Safford, M., Kent, S. T., Osterman, M., Lewis, J. D., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-207870 · Cited by 112
Aletaha, D., Bingham, C. O., Tanaka, Y., Agarwal, P., Kurrasch, R., Tak, P. P., & Popik, S. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30401-4 · Cited by 112
Kivitz, A., Gutiérrez-Ureña, S. R., Poiley, J. E., et al. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39955 · Cited by 110
Rutherford, A. I., Subesinghe, S., Hyrich, K. L., & Galloway, J. B. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-212825 · Cited by 109
Erratum: The emerging safety profile of JAK inhibitors in rheumatic disease
Winthrop, K. L. (2017) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2017.51 · Cited by 106
A Randomized Phase II b Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis
Weinblatt, M. E., McInnes, I. B., Kremer, J. M., Miranda, P., Vencovský, J., Guo, X., White, W. I., Ryan, P. C., Godwood, A., Albulescu, M., et al. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40323 · Cited by 101
Self-citationEmery, P., Rondon, J., Parrino, J., Lin, Y., Pena-Rossi, C., van Hoogstraten, H., Graham, N. M. H., Liu, N., Paccaly, A., Wu, R., et al. (2019) · Rheumatology · doi:10.1093/rheumatology/key361 · Cited by 95
Genovese, M. C., Greenwald, M., Codding, C. E., et al. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40054 · Cited by 92
Genovese, M. C., Weinblatt, M. E., Aelion, J. A., Mansikka, H. T., Peloso, P. M. J., Chen, K., Li, Y., Othman, M. I. A., Khatri, A., Khan, N., et al. (2018) · Arthritis & Rheumatology · doi:10.1002/art.40580 · Cited by 82
Burmester, G. R., McInnes, I. B., Kremer, J. M., Miranda, P., Vencovský, J., Godwood, A., Albulescu, M., Michaels, M. A., Guo, X., Close, D. R., et al. (2018) · Arthritis & Rheumatology · doi:10.1002/art.40420 · Cited by 81
Self-citationGrøn, K. L., Arkema, E. V., Glintborg, B., Mehnert, F., Østergaard, M., Dreyer, L., Nørgaard, M., Krogh, N. S., Askling, J., & Hetland, M. L. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-214326 · Cited by 73
Keystone, E. C., Genovese, M. C., Schlichting, D. E., de la Torre, I., Beattie, S. D., Rooney, T. P., & Taylor, P. C. (2017) · The Journal of Rheumatology · doi:10.3899/jrheum.161161 · Cited by 69
Sirukumab for rheumatoid arthritis: the phase III SIRROUND-D study
Takeuchi, T., Thorne, C., Karpouzas, G. A., Sheng, S., Xu, W., Rao, R., Fei, K., Hsu, B. L., & Tak, P. P. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-211328 · Cited by 68
Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study
Machado, M. A. D. Á., de Moura, C. S., Guerra, S. F., et al. (2018) · Arthritis Research & Therapy · doi:10.1186/s13075-018-1539-6 · Cited by 65
Takeuchi, T., Tanaka, Y., Yamanaka, H., Amano, K., Nagamine, R., Park, W., Shiozawa, K., Tsukano, M., Wei, J. C., Shao, J., et al. (2015) · Modern Rheumatology · doi:10.3109/14397595.2015.1074648 · Cited by 61
Wasko, M. C., Dasgupta, A., Sears, G. I., Fries, J. F., & Ward, M. M. (2015) · Arthritis Care & Research · doi:10.1002/acr.22722 · Cited by 59
LANGE, E. L., Blizzard, L., Venn, A., Francis, H., & Jones, G. (2016) · Rheumatology · doi:10.1093/rheumatology/kew214 · Cited by 59
Movahedi, M., Costello, R., Lunt, M., Pye, S. R., Sergeant, J. C., & Dixon, W. G. (2016) · European Journal of Epidemiology · doi:10.1007/s10654-016-0167-1 · Cited by 58
Park, W., Majstorović, L. B., Milaković, D., Kasay, A. B., El-Khouri, E. C., Irazoque-Palazuelos, F. C., Cons-Molina, F., Shesternya, P. A., Miranda, P., Medina-Rodriguez, F. G., et al. (2018) · mAbs · doi:10.1080/19420862.2018.1487912 · Cited by 55
Meißner, Y., Richter, A., Manger, B., Tony, H.-P., Wilden, E., Listing, J., Zink, A., & Strangfeld, A. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-211209 · Cited by 47
Mori, S., Yoshitama, T., Hidaka, T., Sakai, F., Hasegawa, M., Hashiba, Y., Suematsu, E., Tatsukawa, H., Mizokami, A., Yoshizawa, S., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0179179 · Cited by 47
Kim, S. C., Solomon, D. H., Rogers, J. R., Gale, S. L., Klearman, M., Sarsour, K., & Schneeweiß, S. (2018) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2018.03.012 · Cited by 47
Monemi, S., Berber, E., Sarsour, K., Wang, J., Lampl, K. L., Bharucha, K. N., & Pethoe-Schramm, A. (2016) · Rheumatology and Therapy · doi:10.1007/s40744-016-0037-z · Cited by 45
Tanaka, Y., Ishii, T., Cai, Z., Schlichting, D. E., Rooney, T. P., & Macias, W. L. (2017) · Modern Rheumatology · doi:10.1080/14397595.2017.1307899 · Cited by 41
Calabrese, L. H., Abud‐Mendoza, C., Lindsey, S. M., Lee, S., Tatulych, S., Takiya, L., Iikuni, N., Soma, K., Luo, Z., & Fleischmann, R. (2019) · Arthritis Care & Research · doi:10.1002/acr.24010 · Cited by 39
Genovese, M. C., van Adelsberg, J., Fan, C., Graham, N. M. H., van Hoogstraten, H., Parrino, J., Mangan, E. K., Spindler, A. J., Huizinga, T. W. J., van der Heijde, D. M. F. M., et al. (2018) · Lara D. Veeken · doi:10.1093/rheumatology/key121 · Cited by 37
Jani, M., Dixon, W. G., Kearsley‐Fleet, L., Bruce, I. N., Chinoy, H., Barton, A. C., Lunt, M., Watson, K. D., BSRBR-RA*, Symmons, D. P. M., et al. (2017) · RMD Open · doi:10.1136/rmdopen-2016-000314 · Cited by 36
Genovese, M. C., Braun, D. K., Erickson, J., Berclaz, P., Banerjee, S., Heffernan, M. P., & Carlier, H. (2015) · The Journal of Rheumatology · doi:10.3899/jrheum.140831 · Cited by 35
Harrold, L. R., Litman, H. J., Saunders, K. C., Dandreo, K. J., Gershenson, B. G., Greenberg, J. D., Low, R., Stark, J. L., Suruki, R., Jaganathan, S., et al. (2018) · Arthritis Research & Therapy · doi:10.1186/s13075-017-1496-5 · Cited by 35
Kim, S. C., Schneeweiß, S., Liu, J., Karlson, E. W., Katz, J. N., Feldman, S., & Solomon, D. H. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39689 · Cited by 33
Risk of Hypersensitivity to Biologic Agents Among Medicare Patients With Rheumatoid Arthritis
Yun, H., Xie, F., Beyl, R. N., Chen, L., Lewis, J. D., Saag, K. G., & Curtis, J. R. (2016) · Arthritis Care & Research · doi:10.1002/acr.23141 · Cited by 30
Taylor, P. C., Schiff, M. H., Wang, Q., Jiang, Y., Zhuang, Y., Kurrasch, R., Daga, S., Rao, R., Tak, P. P., & Hsu, B. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-212496 · Cited by 28
Silva-Fernández, L., Cock, D. D., Lunt, M., Low, A., Watson, K. D., BSRBR-RA Contributors Group, Symmons, D. P. M., & Hyrich, K. L. (2017) · Lara D. Veeken · doi:10.1093/rheumatology/kex304 · Cited by 24
Mease, P. J., Jeka, S., Jaller, J. J., Kitumnuaypong, T., Louthrenoo, W., Mann, H. F., Matsievskaia, G., Soriano, E. R., Jia, B., Wang, C., et al. (2017) · The Journal of Rheumatology · doi:10.3899/jrheum.161238 · Cited by 23
Takeuchi, T., Yamanaka, H., Harigai, M., Tamamura, R., Kato, Y., Ukyo, Y., Nakano, T., Hsu, B., & Tanaka, Y. (2018) · Arthritis Research & Therapy · doi:10.1186/s13075-018-1536-9 · Cited by 18
Herrinton, L. J., Ray, G. T., Curtis, J. R., Wu, J. J., FIREMAN, B. H., Liu, L., & Goldfien, R. D. (2018) · The Permanente Journal · doi:10.7812/tpp/17-101 · Cited by 4
Cited by
Smolen, J. S., Landewé, R. B. M., Bijlsma, J. W. J., Burmester, G. R., Dougados, M., Kerschbaumer, A., McInnes, I. B., Sepriano, A., van Vollenhoven, R. F., de Wit, M., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-216655 · Cited by 2,710
Self-citationSmolen, J. S., Landewé, R., Bijlsma, J., Burmester, G., Chatzidionysiou, K., Dougados, M., Nam, J., Ramiro, S., Voshaar, M., van Vollenhoven, R., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210715 · Cited by 2,057
Self-citationCytokine Storm in COVID-19: The Current Evidence and Treatment Strategies
Tang, Y., Liu, J., Zhang, D., Xu, Z., Ji, J., & Wen, C. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01708 · Cited by 1,094
“Application of synthetic disease-modifying antirheumatic drugs (DMARDs) and biologic DMARDs to downregulate cytokine expression in RA increases the risk of infection (59, 60).”
BackgroundASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update
Ramiro, S., Nikiphorou, E., Sepriano, A., Ortolan, A., Webers, C., Baraliakos, X., Landewé, R. B. M., Van den Bosch, F. E., Boteva, B., Bremander, A., et al. (2023) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2022-223296 · Cited by 992
Self-citationCOVID-19 infection and rheumatoid arthritis: Faraway, so close
Favalli, E. G., Ingegnoli, F., De Lucia, O., Cincinelli, G., Cimaz, R., & Caporali, R. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102523 · Cited by 454
Metadata
- Authors
- Sepriano, A., Kerschbaumer, A., Smolen, J. S., van der Heijde, D., Dougados, M., van Vollenhoven, R., McInnes, I. B., Bijlsma, J. W., Burmester, G. R., de Wit, M., Falzon, L., & Landewé, R.
- Venue
- Annals of the Rheumatic Diseases
- Publisher
- Elsevier BV
- Published
- 2020-06
- Volume
- 79
- Issue
- 6
- Pages
- 760-770
- ISSN
- 0003-4967 (ISSN-L)
- OpenAlex
- W4247851911
- Cited by
- 275
- References
- 85
- FWCI
- 9.54
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.